Viral Vector Production (Research-use) Market Size, Share & Trends Analysis Report By Vector Type (Adenovirus, AAV, Lentivirus), By Application, By Workflow, By End Use, By Region, And Segment Forecasts, 2021 - 2028

Viral Vector Production (Research-use) Market Size, Share & Trends Analysis Report By Vector Type (Adenovirus, AAV, Lentivirus), By Application, By Workflow, By End Use, By Region, And Segment Forecasts, 2021 - 2028

Viral Vector Production (Research-use) Market Growth & Trends

The global viral vector production (research-use) market size is expected to reach USD 3.9 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 18.8% from 2021 to 2028. The expanding research base for advanced therapies has primarily driven the market for research applications including preclinical, clinical, and investigational studies.

The outbreak of the COVID-19 pandemic has created lucrative opportunities for the market players, particularly in the vaccine manufacturing sector. The application of viral vectors in vaccine development against SARS-CoV-2 has witnessed remarkable growth in the fiscal year 2020. By far, the manufacturing of viral vectors for research use is impeded by a lack of production capacity to fulfill the growing market needs.

Thus, operating key stakeholders are engaged in implementing new approaches to overcome these challenges and expand production capacities. The improving ratio of clinical success to the number of clinical trials of gene and cell therapy products is a testament to the enhancing manufacturing capabilities.

Currently, several new gene therapy products are in the late stages of development and the pipeline continues to expand across the globe. The forward momentum for the advanced therapy arena is anticipated to drive investment to conduct research for the development of safe viral vectors and therapies.

Viral Vector Production (Research-use) Market Report Highlights

• Adeno-associated virus (AAV) accounted for the largest revenue share in 2020. Proven records of non-pathogenicity are one of the important key factors boosting the adoption of this segment
• Recently, usage of AAV is rising considerably across several therapeutic areas, consequently witnessing a significant boost in adoption rate throughout the forecast period
• In terms of revenue share, the downstream processing segment dominated the market in 2020 owing to highly complex polishing and purification procedures of final products
• Furthermore, the growing demand for viral vectors due to their increased adoption as therapeutics has led to an increase in the need for optimizing downstream and upstream workflows
• This is driving investment flow in both segments, resulting in a significant share of upstream processing
• Given the extensive efforts in COVID-19 vaccine development, the application of viral vectors in the vaccine development segment has witnessed tremendous growth, resulting in the largest revenue share of this segment in 2020
• The research institutes segment dominated the market in terms of revenue share in 2020. The increasing involvement of scientific communities in gene and cell therapy research has driven the revenue flow in this segment
• North America captured the maximum revenue share in 2020 with the U.S. at the forefront
• One major factor that has contributed to the larger share of this regional market is the presence of a substantial number of centers and institutes that are engaged in the R&D of advanced therapies
• Investments made by the federal bodies for the expansion of cell therapy research base in the region are anticipated to enhance the growth of the market in North America
• The key market players are engaged in collaboration with pharma companies to serve their viral-vector-based research needs pertaining to advanced therapy development